FSD Pharma Inc. Files 6-K With April Update
Ticker: QNTM · Form: 6-K · Filed: Apr 22, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, company-update
TL;DR
FSD Pharma filed a 6-K on 4/22/24 with a press release update. CFO Nathan Coyle signed.
AI Summary
FSD Pharma Inc. filed a Form 6-K on April 22, 2024, to report its activities for the month. The filing includes a press release providing an update on the company's progress. Nathan Coyle, Chief Financial Officer, signed the report.
Why It Matters
This filing provides a routine update from FSD Pharma Inc. to its investors, detailing recent company activities and potentially signaling future strategic directions.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) providing a company update, not indicating significant new risks or opportunities.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- April 22, 2024 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed by FSD Pharma Inc. pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of April 2024.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
The report was signed by Nathan Coyle, Chief Financial Officer, on April 22, 2024.
What is the primary business of FSD Pharma Inc. according to the filing?
FSD Pharma Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where is FSD Pharma Inc. headquartered?
FSD Pharma Inc.'s principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario, Canada.
What exhibits are included with this Form 6-K?
This Form 6-K includes Exhibit 99.1, which is a Press Release providing another update from FSD Pharma.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-04-22 08:01:19
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 21KB
- fsd_ex991img2.jpg (GRAPHIC) — 6KB
- 0001654954-24-004830.txt ( ) — 41KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: April 22, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3